VolitionRx Limited (VNRX)
VolitionRx Statistics
Share Statistics
VolitionRx has 100.75M shares outstanding. The number of shares has increased by 15.72% in one year.
Shares Outstanding | 100.75M |
Shares Change (YoY) | 15.72% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 21.27% |
Shares Floating | 74.6M |
Failed to Deliver (FTD) Shares | 2.5K |
FTD / Avg. Volume | 1.45% |
Short Selling Information
The latest short interest is 690.56K, so 0.7% of the outstanding shares have been sold short.
Short Interest | 690.56K |
Short % of Shares Out | 0.7% |
Short % of Float | 0.88% |
Short Ratio (days to cover) | 4.08 |
Valuation Ratios
The PE ratio is -1.93 and the forward PE ratio is -12.25. VolitionRx's PEG ratio is 0.05.
PE Ratio | -1.93 |
Forward PE | -12.25 |
PS Ratio | 42.09 |
Forward PS | 0.2 |
PB Ratio | -2.08 |
P/FCF Ratio | -1.98 |
PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for VolitionRx.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52, with a Debt / Equity ratio of -0.07.
Current Ratio | 0.52 |
Quick Ratio | 0.52 |
Debt / Equity | -0.07 |
Debt / EBITDA | -0.07 |
Debt / FCF | -0.07 |
Interest Coverage | -79.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $14.51K |
Profits Per Employee | $-317.27K |
Employee Count | 85 |
Asset Turnover | 0.13 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -20.45% in the last 52 weeks. The beta is 1.16, so VolitionRx's price volatility has been higher than the market average.
Beta | 1.16 |
52-Week Price Change | -20.45% |
50-Day Moving Average | 0.56 |
200-Day Moving Average | 0.63 |
Relative Strength Index (RSI) | 42.65 |
Average Volume (20 Days) | 171.84K |
Income Statement
In the last 12 months, VolitionRx had revenue of 1.23M and earned -26.97M in profits. Earnings per share was -0.31.
Revenue | 1.23M |
Gross Profit | 1.23M |
Operating Income | -27.02M |
Net Income | -26.97M |
EBITDA | -25.58M |
EBIT | -26.92M |
Earnings Per Share (EPS) | -0.31 |
Balance Sheet
The company has 3.26M in cash and 1.87M in debt, giving a net cash position of 1.4M.
Cash & Cash Equivalents | 3.26M |
Total Debt | 1.87M |
Net Cash | 1.4M |
Retained Earnings | -229.54M |
Total Assets | 9.4M |
Working Capital | -3.73M |
Cash Flow
In the last 12 months, operating cash flow was -25.89M and capital expenditures -277.5K, giving a free cash flow of -26.17M.
Operating Cash Flow | -25.89M |
Capital Expenditures | -277.5K |
Free Cash Flow | -26.17M |
FCF Per Share | -0.3 |
Margins
Gross margin is 100%, with operating and profit margins of -2190.9% and -2186.27%.
Gross Margin | 100% |
Operating Margin | -2190.9% |
Pretax Margin | -2186.27% |
Profit Margin | -2186.27% |
EBITDA Margin | -2073.65% |
EBIT Margin | -2190.9% |
FCF Margin | -2121.68% |
Dividends & Yields
VNRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for VNRX is $3.75, which is 665.3% higher than the current price. The consensus rating is "Buy".
Price Target | $3.75 |
Price Target Difference | 665.3% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Scores
Altman Z-Score | -43.16 |
Piotroski F-Score | 3 |